3-Feb-2023
Catalyst watch: Google talks AI, Nordstrom drama and Canada Goose event
Seeking Alpha News (Fri, 3-Feb 2:30 PM ET)
Bright Green stock slides after soaring as much as 260% in prior session
Seeking Alpha News (Thu, 2-Feb 2:02 PM ET)
Cannabis producer Bright Green stock soars 200% on $500M investment
Seeking Alpha News (Wed, 1-Feb 12:27 PM ET)
Aurora Cannabis to Host Second Quarter Fiscal Year 2023 Investor Conference Call
PRNewswire (Thu, 26-Jan 7:00 AM ET)
PRNewswire (Wed, 4-Jan 7:00 AM ET)
Aurora's Greybeard Brand Wins KIND Magazine's 'Best Diamonds of the Year' Award
PRNewswire (Fri, 9-Dec 11:36 AM ET)
PRNewswire (Mon, 5-Dec 7:00 AM ET)
High Tide Becomes Top Revenue-Generating Cannabis Company in Canada
PRNewswire (Tue, 22-Nov 6:00 AM ET)
Aurora Cannabis Announces Results of 2022 Annual General and Special Meeting
PRNewswire (Mon, 14-Nov 6:09 PM ET)
Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael '71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.
Aurora Cannabis - Common Shares trades on the NASDAQ stock market under the symbol ACB.
As of February 3, 2023, ACB stock price declined to $1.06 with 8,557,367 million shares trading.
ACB has a beta of 1.19, meaning it tends to be more sensitive to market movements. ACB has a correlation of 0.09 to the broad based SPY ETF.
ACB has a market cap of $343.79 million. This is considered a Small Cap stock.
Last quarter Aurora Cannabis - Common Shares reported $38 million in Revenue and -$.13 earnings per share. This fell short of revenue expectation by $-1 million and missed earnings estimates by -$.04.
In the last 3 years, ACB stock traded as high as $26.40 and as low as $.82.
The top ETF exchange traded funds that ACB belongs to (by Net Assets): MJ, ONEQ, DFIC, DFIS, DFAI.
ACB has underperformed the market in the last year with a return of -73.2%, while the SPY ETF lost -6.3%. In the last 3 month period, ACB fell short of the market, returning -23.2%, while SPY returned +11.6%. However, in the most recent 2 weeks ACB has outperformed the stock market by returning +9.5%, while SPY returned +4.2%.
ACB support price is $1.08 and resistance is $1.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACB stock will trade within this expected range on the day.